摘要
目的 利用串联质谱标签技术(TMT)技术筛选能预测路氏八段锦治疗纤维肌痛症(FM)疗效的血清差异蛋白,以指导临床精准治疗。方法 以疼痛视觉模拟评分(VAS)改善30%作为界值,从完成12周路氏八段锦干预的FM患者中筛选出有效组(VAS 30%)和无效组(VAS<30%)各5例,应用TMT技术筛选疗效相关的血清差异蛋白,并进行生物信息学分析。结果 路氏八段锦有效组与无效组间共鉴定出25个差异蛋白,包括18个上调和7个下调的蛋白,其中包含补体成分4A(C4A),补体成分5(C5)和补体因子1(CF1)等在内的补体系统成分对路氏八段锦的疗效具有预测价值。KEGG富集分析表明路氏八段锦主要作用通路为补体和凝集酶途径。结论 FM患者外周血中补体系统相关蛋白C4A、C5及CF1对路氏八段锦治疗FM的疗效具有潜在的预测价值。
Objective To screen serum differential proteins that can predict the efficacy of Lu's Ba-Duan-Jin in the treatment of fibromyalgia(FM)by tandem mass labeling(TMT)technology,so as to guide clinical precise treatment.Methods With the improvement of visual analogue scale(VAS)30%as the cutoff value,5 cases of effective group(VAS 30%)and 5 cases of ineffective group(VAS<30%)were selected from FM patients who completed 12 weeks of Lu's Ba-Duan-Jin intervention.TMT technology was used to screen serum differential proteins related to efficacy,and bioinformatics analyses were performed.Results A total of 25 differential proteins were identified between the effective group and the ineffective group,including 18 up-regulated and 7 down-regulated proteins.Among them,the complement system components including C4A,C5,and complement factor 1(CF1)were of predictive value for the efficacy of Lu's Ba-Duan-Jin.KEGG enrichment analysis showed that the main pathways were complement and thrombin pathway.Conclusions The complement system-related proteins C4A,C5,and CF1 in peripheral blood of patients with FM had potential predictive value for the efficacy of Lu's Ba-Duan-Jin in the treatment of FM.
作者
李延婷
龙梅娟
李阳
焦娟
孙雨若
LI Yan-ting;LONG Mei-juan;LI Yang;JIAO Juan;SUN Yu-ruo(Department of Rheumatology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing,100053)
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2023年第8期930-936,共7页
Chinese Journal of Integrated Traditional and Western Medicine
基金
国家自然科学基金资助项目(No.8187152388)
中国中医科学院科技创新工程(No.CI2021A01505)。
关键词
纤维肌痛症
蛋白质组学
路氏八段锦
疗效
差异蛋白
fibromyalgia syndrome
proteomics
Lu's Ba-Duan-Jin
efficacy
differentially expressed proteins
